drugset / Trial / NCT05576038

Tryptophan for Impaired AhR Signaling in Celiac Disease

NCT05576038

Recruiting 50 enrolled McMaster University
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a prospective, randomized, double-blind, placebo-controlled exploratory trial to evaluate the effect of L-tryptophan supplementation on celiac-related symptoms in individuals who have biopsy-confirmed celiac disease (CeD) and symptoms non-responsive to a gluten-free diet (GFD). Fifty participants, aged 18 to 75 years, who self-report persistent CeD-related symptoms despite taking a GFD for more than 1 year and who score \> 40 on the Celiac Symptom Index (CSI) will be randomized to receive L-tryptophan or placebo for 3 weeks.

Timeline

Start
2022-12-01
Primary completion
2025-04-01
Completion
2025-06-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator amino acids Unknown 1000 mg Oral